Cyclotek supports the Australian Government’s decision to expand access to Medicare-funded prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging for eligible men with recurrent prostate cancer.
From 1 November 2026, eligible men with recurrent prostate cancer will be able to access Medicare-funded PSMA PET scans on an annual basis, replacing the existing limitation of two scans per lifetime.
The expansion builds on the Medical Services Advisory Committee (MSAC) application jointly submitted by Cyclotek and the Australasian Association of Nuclear Medicine Specialists (AANMS), which led to the establishment of Medicare Benefits Schedule (MBS)-funded PSMA PET imaging for the staging and restaging of prostate cancer in Australia.
Prostate cancer remains the most commonly diagnosed cancer among Australian men, with close to 29,000 men diagnosed each year.
PSMA PET imaging is used in the assessment and management of prostate cancer and provides clinicians with information to support treatment planning and ongoing patient management.
The amendment to the MBS is expected to improve access to Medicare-funded PSMA PET imaging for eligible patients and reduce barriers to ongoing disease monitoring.
Media Contact:
Paul Higgins
+61423 901 304
Codex Communications (on behalf of Cyclotek)
contact@codexcomms.com.au
About Cyclotek:
Cyclotek is a leading radiopharmaceutical company supplying advanced diagnostic and therapeutic products for clinical use and clinical trials across Australia and New Zealand. With a multi-site GMP manufacturing network and more than two decades of operational excellence, Cyclotek provides reliable access to high-quality PET radiopharmaceuticals for over 150,000 patients each year.
The company specialises in enabling earlier and more precise diagnosis through innovative PET tracers that provide patient-specific insights into cancer, neurological diseases, and other serious conditions. These tracers help clinicians detect disease earlier, assess progression more accurately, and plan treatment with greater confidence. When paired with emerging radionuclide therapies, they support a comprehensive, non-invasive approach to personalised disease management.
Cyclotek is also deeply committed to research, translation, and the development of new radiopharmaceuticals, working with global partners, universities, and clinical trial sponsors to expand access to next-generation diagnostic and therapeutic agents. This includes supporting First-in-Human studies, specialised manufacturing requirements, and technology transfer for investigational compounds.
Beyond manufacturing, Cyclotek serves as a regional capability partner—focused on quality, safety, supply resilience, and collaborative innovation. The company’s mission is to strengthen radiopharmaceutical access, contribute to more cost-effective and patient-centred healthcare, and help build the infrastructure required for precision medicine across the Asia-Pacific region.